This practice offers ketamine therapy to treat treatment-resistant depression (TRD) which involves prescribing esketamine (Spravato).

Spravato is a nasal spray formulation of esketamine, an NMDA receptor antagonist, approved by the FDA to treat depression. It is used alongside an oral antidepressant for patients who have not responded adequately to at least two antidepressant treatments.